Peter G. Linde

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

SpineVision SA develops and markets implants for the treatment of spinal disorders. It also designs instrumentation for the spinal treatments. Its products include Flex 2, Lumis, Plus/X-Plus, ULIS, Unithread, Spacevisions, and C3. The firm also offers solutions for spinal pathologies, such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma, and tumors. The company was founded by Gérard Vanacker on July 16, 1999 and is headquartered in Antony, France.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA.

AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.

Andrew Alliance SA develops liquid handling solutions. Its product, Andrew, is a novel liquid handling robot designed for pipetting process. The firm's products include Andrew models, consumable dominos, protocol design, and enabling accessories. The company was founded by Piero Zucchelli, Giorgio Horak, and Antoine Jordan in March 2011 and is headquartered in Vernier, Switzerland.

eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA.

Hibercell, Inc. specializes on tumor dormancy detection and therapeutics. It provides treatment for primary tumors, metastatic cancer. The company was founded by Alan Rigby, Julio Aguirre-Ghiso, and Ari Nowacek and is headquartered in New York, NY.

Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA.

Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture.

Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.